{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:33:23Z","timestamp":1788244403696,"version":"build-2803163510"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","award":["2018-000229-30"],"award-info":[{"award-number":["2018-000229-30"]}],"id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite significant advancements in atopic dermatitis (AD) treatment, the underlying pathogenesis remains unclear. Understanding flare and remission mechanisms is essential for understanding disease course, evaluating treatment and developing therapeutic strategies. Although biomarkers show promise for assessing disease severity, their identification, validation and clinical utility demand further research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate inflammatory changes involved in AD flares and remissions, we studied changes in expression of 368 circulating biomarkers during cyclosporine (CsA) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included 40 AD patients experiencing a disease flare and starting CsA treatment. Serum samples were collected at baseline, after 2 and 4 weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CsA treatment induced a rapid improvement of disease severity and reduced proteins related to Th2, Th1 and Th17 pathways. Four novel markers, FKBP1B, PDLIM7, MAP2K6 and EIF4G1 demonstrated decreased expression levels after treatment. In addition, CCL17\/TARC and OX40 levels showed a strong correlation with disease severity. Interestingly, NME3, SMOC2, and GAL showed increased expression after treatment. We identified four biomarkers that may be linked to the pathogenesis of flares and remissions. Lastly, we identified OX40 as a potential biomarker for disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified four novel serum biomarkers possibly related to treatment effect and we identified OX40 as a potential serum biomarker for assessing disease severity. These findings enhance understanding of AD pathogenesis and offer tools for monitoring therapeutic response and disease severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0346686","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:35:36Z","timestamp":1776706536000},"page":"e0346686","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum proteomic changes in atopic dermatitis patients treated with cyclosporine"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7391-5266","authenticated-orcid":true,"given":"Jill Isabelle","family":"Olydam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Litman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Nijsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Hoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6033-1305","authenticated-orcid":true,"given":"Witte","family":"Koopmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba Milena","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DirkJan","family":"Hijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"10023","key":"pone.0346686.ref001","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"S Weidinger","year":"2016","journal-title":"Lancet"},{"key":"pone.0346686.ref002","doi-asserted-by":"crossref","first-page":"354250","DOI":"10.1155\/2014\/354250","article-title":"Atopic dermatitis: natural history, diagnosis, and treatment","volume":"2014","author":"SF Thomsen","year":"2014","journal-title":"ISRN Allergy"},{"issue":"11","key":"pone.0346686.ref003","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/exd.14389","article-title":"Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease","volume":"30","author":"JT Sims","year":"2021","journal-title":"Exp Dermatol"},{"issue":"3","key":"pone.0346686.ref004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease","volume":"137","author":"B Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"pone.0346686.ref005","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2022.12.050","article-title":"Proteomic characterization of atopic dermatitis blood from infancy to adulthood","volume":"88","author":"E Del Duca","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"pone.0346686.ref006","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis","volume":"140","author":"JL Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"pone.0346686.ref007","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jaci.2017.06.046","article-title":"EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients","volume":"140","author":"JL Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"pone.0346686.ref008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"DS Bakker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"pone.0346686.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.06.008","article-title":"EASI p-EASI: Predicting Disease Severity in Patients with Atopic Dermatitis Treated with Tralokinumab","volume":"142","author":"JI Olydam","year":"2022","journal-title":"J Invest Dermatol"},{"key":"pone.0346686.ref010","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"S Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"pone.0346686.ref011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2133.2001.03948.x","article-title":"A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy","volume":"144","author":"AM Farrell","year":"2001","journal-title":"Br J Dermatol"},{"issue":"8760","key":"pone.0346686.ref012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"JM Sowden","year":"1991","journal-title":"Lancet"},{"issue":"4","key":"pone.0346686.ref013","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.1993.tb03170.x","article-title":"Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial","volume":"129","author":"MS Salek","year":"1993","journal-title":"Br J Dermatol"},{"issue":"5","key":"pone.0346686.ref014","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"T van Joost","year":"1994","journal-title":"Br J Dermatol"},{"issue":"4","key":"pone.0346686.ref015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/09546634.2019.1662881","article-title":"Outcomes of prolonged and low-dose ciclosporin in an Asian population","volume":"32","author":"E Choi","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"pone.0346686.ref016","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.14896","article-title":"Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands","volume":"32","author":"FM Garritsen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"pone.0346686.ref017","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"S Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"pone.0346686.ref018","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"D Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"pone.0346686.ref019","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"A Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"pone.0346686.ref020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"JM Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"issue":"2","key":"pone.0346686.ref021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards","volume":"74","author":"M Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"pone.0346686.ref022","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"G Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"12","key":"pone.0346686.ref023","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"CR Charman","year":"2004","journal-title":"Arch Dermatol"},{"issue":"4","key":"pone.0346686.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"E Assarsson","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0346686.ref025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Y Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"pone.0346686.ref026","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s000180050299","article-title":"Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts","volume":"55","author":"SF G\u00f6thel","year":"1999","journal-title":"Cell Mol Life Sci"},{"issue":"6380","key":"pone.0346686.ref027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/357695a0","article-title":"Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation","volume":"357","author":"NA Clipstone","year":"1992","journal-title":"Nature"},{"issue":"24","key":"pone.0346686.ref028","doi-asserted-by":"crossref","first-page":"14169","DOI":"10.1073\/pnas.2335979100","article-title":"Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells","volume":"100","author":"S Dubois","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"pone.0346686.ref029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/bies.200900148","article-title":"Nucleocytoplasmic functions of the PDZ-LIM protein family: new insights into organ development","volume":"32","author":"J Krcmery","year":"2010","journal-title":"Bioessays"},{"issue":"20","key":"pone.0346686.ref030","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.3390\/cancers15205042","article-title":"PDZ and LIM domain-encoding genes: their role in cancer development","volume":"15","author":"X Jiang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"pone.0346686.ref031","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3389\/fimmu.2020.01559","article-title":"PDLIM7 Synergizes With PDLIM2 and p62\/Sqstm1 to Inhibit Inflammatory Signaling by Promoting Degradation of the p65 Subunit of NF-\u03baB","volume":"11","author":"A Jodo","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"pone.0346686.ref032","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/emboj.2010.312","article-title":"Multiple elements in the eIF4G1 N-terminus promote assembly of eIF4G1\u2022PABP mRNPs in vivo","volume":"30","author":"E-H Park","year":"2011","journal-title":"EMBO J"},{"key":"pone.0346686.ref033","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-biochem-013118-111042","article-title":"The organizing principles of eukaryotic ribosome recruitment","volume":"88","author":"J Pelletier","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"pone.0346686.ref034","doi-asserted-by":"crossref","first-page":"1346383","DOI":"10.3389\/fphar.2024.1346383","article-title":"Knockdown of EIF4G1 in NSCLC induces CXCL8 secretion","volume":"15","author":"Z He","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0346686.ref035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2023.06.003","article-title":"Modulation of IL-33\/ST2 signaling as a potential new therapeutic target for cardiovascular diseases","author":"PV Thanikachalam","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"pone.0346686.ref036","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/MCB.19.4.2435","article-title":"Mitogen-activated protein kinases: specific messages from ubiquitous messengers","volume":"19","author":"HJ Schaeffer","year":"1999","journal-title":"Mol Cell Biol"},{"issue":"1","key":"pone.0346686.ref037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/s13018-025-06037-y","article-title":"METTL14 mediates the m6A methylation of miR-29a-3p, thereby activating the MAP2K6 signaling pathway and exacerbating the inflammatory response associated with spinal tuberculosis","volume":"20","author":"L Feng","year":"2025","journal-title":"J Orthop Surg Res"},{"issue":"51","key":"pone.0346686.ref038","doi-asserted-by":"crossref","first-page":"49205","DOI":"10.1074\/jbc.M209685200","article-title":"Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1\/ST2. A role for Jun N-terminal kinase in IL-4 induction","volume":"277","author":"EK Brint","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0346686.ref039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1523-1747.1998.00071.x","article-title":"Effect of AP1 transcription factors on the regulation of transcription in normal human epidermal keratinocytes","volume":"110","author":"A Rossi","year":"1998","journal-title":"J Invest Dermatol"},{"key":"pone.0346686.ref040","article-title":"Signalling in inflammatory skin disease by AP-1 (Fos\/Jun)","volume":"33","author":"\u00d6 Ulu\u00e7kan","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"37","key":"pone.0346686.ref041","article-title":"FRA1:c-JUN:HDAC1 complex down-regulates filaggrin expression upon TNF\u03b1 and IFN\u03b3 stimulation in keratinocytes","volume":"119","author":"SS Ahn","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"pone.0346686.ref042","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"T Kawai","year":"2011","journal-title":"Immunity"},{"key":"pone.0346686.ref043","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2019.01412","article-title":"Structural Basis of IL-1 Family Cytokine Signaling","volume":"10","author":"JK Fields","year":"2019","journal-title":"Front Immunol"},{"issue":"15","key":"pone.0346686.ref044","doi-asserted-by":"crossref","first-page":"10865","DOI":"10.1074\/jbc.M113.544809","article-title":"Interleukin 1\/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner","volume":"289","author":"L Cushing","year":"2014","journal-title":"J Biol Chem"},{"key":"pone.0346686.ref045","doi-asserted-by":"crossref","first-page":"1133354","DOI":"10.3389\/fimmu.2023.1133354","article-title":"Regulation of innate immune signaling by IRAK proteins","volume":"14","author":"M Pereira","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0346686.ref046","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"L Ackerman","year":"2023","journal-title":"Nat Med"},{"issue":"683","key":"pone.0346686.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj3289","article-title":"IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases","volume":"15","author":"S Lavazais","year":"2023","journal-title":"Sci Transl Med"},{"issue":"1","key":"pone.0346686.ref048","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"M Croft","year":"2009","journal-title":"Immunol Rev"},{"issue":"12","key":"pone.0346686.ref049","article-title":"OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis - Focus on Rocatinlimab and Amlitelimab","volume":"14","author":"AM Le","year":"2022","journal-title":"Pharmaceutics"},{"key":"pone.0346686.ref050","doi-asserted-by":"crossref","first-page":"1081999","DOI":"10.3389\/fimmu.2023.1081999","article-title":"T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis","volume":"14","author":"C Zheng","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0346686.ref051","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3390\/jcm10122578","article-title":"OX40L-OX40 Signaling in Atopic Dermatitis","volume":"10","author":"M Furue","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0346686.ref052","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target","volume":"25","author":"M Croft","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"pone.0346686.ref053","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3452","article-title":"The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis","volume":"100","author":"JS Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"pone.0346686.ref054","article-title":"Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation","volume":"120","author":"Y-J Liu","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"pone.0346686.ref055","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI33559","article-title":"In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation","volume":"117","author":"D Seshasayee","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"pone.0346686.ref056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"E Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0357330","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:35:45Z","timestamp":1776706545000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346686"}},"subtitle":[],"editor":[{"given":"Xiaosheng","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346686","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}